This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Ophthalmology Podcasts

The Macular Minute

Podcast Series

The Macular Minute Banner
The Macular Minute logo
Welcome to The Macular Minute

Your source for quick expert insights in medical retina

This promotional podcast series has been organised and funded by Bayer and offers

bite-sized education
for UK healthcare professionals. Tune in for insights delivered
one minute at a time
 as we interview leaders in the field on key topics related to EYLEA® (aflibercept) 8 mg.

Click on the below cards to access The Macular Minute podcast episodes.

In this

4-minute
episode, we are joined by
Hani Hasan
, a Consultant Ophthalmologist at Newcastle upon Tyne Hospitals NHS Foundation Trust, to discuss
the implications of reducing the anti-VEGF treatment burden
.

In this

4-minute
episode, we are joined by
Sobha Sivaprasad
, a Consultant Ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust, to discuss
the holistic costs associated with anti-VEGF treatment
.

In this

4-minute
episode, we are joined by
Hani Hasan
,
Rossella Anzidei
 and
Richard Gale
, a panel of three consultant ophthalmologists, to discuss their experience with
the drying effects of EYLEA 8 mg
.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

Meet our expert panel for the spotlighted episodes of The Macular Minute:

Hani Hasan
Sobha Sivaprasad
Rossella Anzidei
Richard Gale

Hani Hasan

Consultant Ophthalmologist at Newcastle upon Tyne Hospitals NHS Foundation Trust

Speaker Disclosures

Speaker and travel grants: AbbVie, Bayer and Roche

 

Sobha Sivaprasad

Consultant Ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust

Speaker Disclosures

Financial support from AbbVie, Amgen, Apellis Pharmaceuticals, Bayer, Biogen, Boehringer Ingelheim, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Kriya Therapeutics, Novartis, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Roche, Sanofi and Stealth BioTherapeutics

 

Rossella Anzidei

Consultant Ophthalmologist at University Hospitals Leicester NHS Trust

Speaker Disclosures:

Speaker and travel grants: AbbVie, Bayer and Novartis

 

Richard Gale

Professor of Ophthalmology at York University and Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust

Speaker Disclosures:

Speaker and travel grants: AbbVie, Alimera Sciences, Allergan, Amgen, Bayer, Biogen, Boehringer Ingelheim, Gilead Sciences, Heidelberg Pharma, Lux Biosciences, Notal Vision, Novartis, Roche, Santen

References

  1. EYLEA® 40 mg/mL Summary of Product Characteristics.
  2. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
  3. Sivaprasad, S. et al. (2024) ‘Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis’, Current Medical Research and Opinion, 40(7), pp. 1221–1233. doi: 10.1080/03007995.2024.2362278. Available at: https://www.tandfonline.com/doi/full/10.1080/03007995.2024.2362278. Accessed: March 2026. This paper has been initiated and funded by Bayer.
  4. PULSAR clinical trial: Lanzetta P et al. Lancet 2024; 403 (10432): 1141-1152.

PP-EYL-GB-3090 | March 2026